The Filing Desk

Cartesian Therapeutics vs Upstream Bio

Cartesian Therapeutics RNAC · Upstream Bio UPB · Pharmaceuticals

Upstream Bio reported revenue of $3 million in fiscal 2025, about the same as Cartesian Therapeutics' $3 million in fiscal 2025. Cartesian Therapeutics' revenue fell 92.8% in its latest year, and Upstream Bio's grew 20.4%. Cartesian Therapeutics had an operating margin of -5127.1%, against -5618.8% at Upstream Bio. Free cash flow was −$79 million at Cartesian Therapeutics and −$133 million at Upstream Bio.

Side by side

Cartesian TherapeuticsUpstream Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$3M$3M
Revenue growth−92.8%20.4%
Revenue growth a year, last 5 years−29.9%—
Gross margin——
Operating margin−5,127.1%−5,618.8%
Net margin−4,658.6%−5,026.0%
Free cash flow−$79M−$133M
Free cash flow margin−2,838.6%−4,675.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count49.6%293.6%
Last close$5.89$2.00
P/E at the last close——
Insider trades, last 12 monthsbought $205,800, sold $258,683sold $104,799
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Cartesian TherapeuticsUpstream Bio
Operating margin
Percent of revenue
Cartesian TherapeuticsUpstream Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cartesian TherapeuticsUpstream Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cartesian Therapeutics and Upstream Bio pages.